ENGINEERINGNET.EU -- The Belgium based tech company Trinean has succeeded in raising 2.7 million euro to further accelerate the development of its premium analytical platform.
This platform comprises spectrophotometry instruments, state-ofthe-art analytical software, proprietary disposables for standardized micro-volume sample analysis and highly flexible lab-automation tools.
The first closing of this financing round was led by the Trineans’ current investors Vesalius Biocapital, Capital-E, Baekeland II Fund and Fidimec.
“The continued support of Trinean’s first-in-class investors allows our company to expand its sales, marketing and distribution channels,” comments Philippe Stas, the recently appointed CEO of the company.
Prior to joining Trinean, Philippe Stas was CEO of Algonomics, a Belgium based biotech service provider, where he ensured the growth and subsequent trade sale of the company to Lonza Group AG in 2009.
Since then, he was the director and main driver of Lonza’s Applied Protein Services division in Cambridge (UK). Earlier, Philippe Stas held positions at Perkin Elmer and Keygene.
Philippe holds a M.Sc. in Bio-engineering (Brussels Univ.), a M.Sc. in Information Technology (Hasselt Univ.), an MBA (Univ. of Liverpool) and AMP at the Vlerick Management School.
Trinean was founded in 2006 as a spin-out of the University of Ghent, Belgium.
